Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
Public ClinicalTrials.gov record NCT03740165. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036)
Study identification
- NCT ID
- NCT03740165
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 1,367 participants
Conditions and interventions
Interventions
- Bevacizumab Biological
- Carboplatin Drug
- Docetaxel Drug
- Olaparib Drug
- Paclitaxel Drug
- Pembrolizumab Biological
- Placebo for olaparib Drug
- Placebo for pembrolizumab Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 17, 2018
- Primary completion
- Aug 25, 2024
- Completion
- Apr 14, 2026
- Last update posted
- May 3, 2026
2018 – 2026
United States locations
- U.S. sites
- 43
- U.S. states
- 24
- U.S. cities
- 40
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham (UAB) ( Site 0036) | Birmingham | Alabama | 35233 | — |
| University of Arizona Cancer Center ( Site 0074) | Tucson | Arizona | 85719 | — |
| Disney Family Cancer Center ( Site 0042) | Burbank | California | 91505 | — |
| Kaiser Permanente Oncology Clinical Trial -Oakland ( Site 0077) | Oakland | California | 94611 | — |
| Kaiser Permanente Oncology Clinical Trials-Roseville ( Site 0084) | Roseville | California | 95661 | — |
| Kaiser Permanente Oncology Clinical Trials-Sacramento ( Site 0083) | Sacramento | California | 95814 | — |
| Kaiser Permanente Oncology Clinical Trial - San Francisco ( Site 0078) | San Francisco | California | 94115 | — |
| Kaiser Permanente Oncology Clinical Trial - Santa Clara ( Site 0079) | Santa Clara | California | 95051 | — |
| Kaiser Permanente N. CA Regional Oncology Clinical Trials ( Site 0008) | Vallejo | California | 94589 | — |
| Kaiser Permanente Oncology Clinical Trial - Walnut Creek ( Site 0080) | Walnut Creek | California | 94596 | — |
| Smilow Cancer Center at Yale-New Haven ( Site 0057) | New Haven | Connecticut | 06511 | — |
| Sarasota Memorial Hospital ( Site 0023) | Sarasota | Florida | 34239 | — |
| Emory School of Medicine ( Site 0053) | Atlanta | Georgia | 30322 | — |
| Northeast Georgia Medical Center ( Site 0029) | Gainesville | Georgia | 30501 | — |
| Memorial Health University Medical Center ( Site 0011) | Savannah | Georgia | 31404 | — |
| Rush University Medical Center ( Site 0019) | Chicago | Illinois | 60612 | — |
| University of Chicago ( Site 0049) | Chicago | Illinois | 60637 | — |
| Dr. Sudarshan K. Sharma, LTD ( Site 0061) | Hinsdale | Illinois | 60521 | — |
| Saint Vincent Hospital and Health Center ( Site 0012) | Indianapolis | Indiana | 46260 | — |
| University of Iowa Hospital and Clinics ( Site 0005) | Iowa City | Iowa | 52242 | — |
| University of Kentucky ( Site 0045) | Lexington | Kentucky | 40536 | — |
| Weinberg Cancer Institute at Franklin Square ( Site 0035) | Baltimore | Maryland | 21237 | — |
| Saint Dominic - Jackson Memorial Hospital ( Site 0072) | Jackson | Mississippi | 39216 | — |
| Washington University - School of Medicine ( Site 0062) | St Louis | Missouri | 63110 | — |
| Nebraska Methodist Hospital ( Site 0063) | Omaha | Nebraska | 68114 | — |
| Dartmouth Hitchcock Medical Center ( Site 0024) | Lebanon | New Hampshire | 03756 | — |
| MD Anderson Cancer Center at Cooper ( Site 0067) | Camden | New Jersey | 08103 | — |
| Holy Name Medical Center ( Site 0037) | Teaneck | New Jersey | 07666 | — |
| Northwell Health- Monter Cancer Center ( Site 0075) | Lake Success | New York | 11042 | — |
| Sanford Roger Maris Cancer Center ( Site 0082) | Fargo | North Dakota | 58122 | — |
| Miami Valley Hospital [Dayton, OH] ( Site 0073) | Centerville | Ohio | 45459 | — |
| Oncology/Hematology Care Clinical Trials, LLC ( Site 8001) | Cincinnati | Ohio | 45242 | — |
| The Bing Cancer Center ( Site 0044) | Columbus | Ohio | 43214 | — |
| OSU Wexner Medical Center ( Site 0076) | Hilliard | Ohio | 43026 | — |
| Women and Infants Hospital [Providence, RI] ( Site 0039) | Providence | Rhode Island | 02905 | — |
| Sanford Gynecology Oncology ( Site 0004) | Sioux Falls | South Dakota | 57104 | — |
| Texas Oncology, P.A. - Bedford ( Site 8005) | Bedford | Texas | 76022 | — |
| Texas Oncology-Dallas Presbyterian Hospital ( Site 8004) | Dallas | Texas | 75231 | — |
| Parkland Hospital ( Site 0081) | Dallas | Texas | 75235 | — |
| UT Southwestern Medical Center ( Site 0046) | Dallas | Texas | 75390 | — |
| Texas Oncology, P.A. Texas Oncology-Tyler ( Site 8006) | Tyler | Texas | 75702 | — |
| Virginia Cancer Specialists, PC ( Site 8003) | Gainesville | Virginia | 20155 | — |
| MEDICAL COLLEGE OF WISCONSIN ( Site 0064) | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 184 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03740165, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 3, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03740165 live on ClinicalTrials.gov.